Nasdaq

Lantheus Holdings, Inc. Announces FDA Approval of VIALMIX® RFID Device for DEFINITY®

NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global ...
Business Wire

Lantheus Medical Imaging Announces FDA Approval of DEFINITY ® Label Update

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc. (“Lantheus”) today announced U.S. Food and Drug Administration (FDA) approval of an important label update for DEFINITY ® Vial ...
Business Wire

Lantheus Holdings, Inc. Announces FDA Approval of DEFINITY ® Room Temperature

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global ...
health.economictimes.indiatimes

Microbubbles future promising in enhancing diagnostic capabilities, revolutionising treatment methods: GlobalData

London: The ultrasound contrast agents (microbubbles) market is driven by their role in enhancing diagnostic capabilities and revolutionising treatment methods. The demand for microbubbles will stem ...